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Context: In the United States, the postoperative opioid prescriptions have been 
implicated in the so called “opioid epidemic”. In Europe the extent of overprescribing or 
misuse of opioids are unsure.  
Objectives: To describe the proportion of persistent postoperative opioid use of adults 
(>18 Years) in European countries. 
Design: Systematic review of the published data. 
Data sources: We searched the electronic literature databases MEDLINE (Ovid), 
Embase (Ovid), PubMed/MEDLINE and Scopus. 
Eligibility criteria: Studies describing opioid use of adult patients (>18 years) at least 3 
months after surgery.  
Results: 1307 studies were found, and 12 studies were included in the review. The rate 
of opioid users after 3 to 6 months was extracted from the studies and categorised into 
type of the surgery. Nine studies investigated the opioid use after total hip or total knee 
arthroplasties (THA and TKA) and reported opioid user rates between 7.9% and 41% 
after three months. In all included studies a proportion between 2.0% and 41.0% of 
patients were opioid users three months after surgery. The level of evidence varied from 
high to very low. 
Conclusion: To give statements about the persistent opioid use about specific countries 
or surgery types is not possible. Because of the observed ranges, we can neither confirm 
nor rule out a possible public health problem linked to the persistent use of opioids in 
Europe. 





The persistent use of opioids after surgery has been rising in the last years and can be 
associated with tolerance, sedation, dizziness, nausea, vomiting, constipation, physical 
dependence, and respiratory depression.1 Furthermore, a prolonged use of opioids is 
associated with increasing numbers of opioid misuse, opioid-caused mortality and a high 
prevalence of opioid-addiction.2,3 In the United States (US), the postoperative opioid 
prescriptions have been implicated in the so called “opioid epidemic”. 
Kent et al. (2019) published a systematic review about the incidence rates of persistent 
opioid use after surgery in North America.4 They defined “persistent postoperative opioid 
use” for opioid-naïve patients as using “opioids for 60 days during postoperative days 90 
to 365” and for patients who use opioids before surgery as “any increase in opioid use 
during postoperative days 90 to 365, relative to opioid use in the 90 days before 
surgery”.4 They found reported incidence rates between 0.36 % and 85 %.  
In Europe, after surgery, overprescribing or misuse of opioids may differ from the 
situation in North America, even if the opioid prescription rates, in general, are rising. 
Even if continentwide comprehensive data are lacking, consistent evidence is available 
in the UK. In Scotland, the prescriptions of strong opioids more than doubled between 
2003 and 2012.5 In England, between 1998 and 2016, a parallel increase of 127% (after 
correcting for total oral morphine equivalency) has been observed.6 However, no global 
assessment has been done regarding the persistent postoperative use of opioids in 
Europe.  
The aim of this systematic review is to summarize the current published data on the 
proportion of persistent postoperative opioid use of adults (>18 Years) in European 
countries in comparison to North America. The primary outcome is the rates of persistent 
postoperative opioid use, defined as using opioids longer than 3 months.7 This is a 
simplified version of the proposed definition of Kent et al (2019) (14) and the “American 
Society of Enhanced Recovery (ASER) and Perioperative Quality Initiative (POQI) joint 
consensus”, maximising the data collection.  
 
METHODS  
Protocol and registration  
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The Review was registered under PROSPERO and has the registration number: 
CRD42019154292 
Search  
We searched the electronic literature databases MEDLINE (Ovid), Embase (Ovid), 
PubMed/MEDLINE and Scopus. 
The search string used was adapted from the search string of Kent et al (2019) to the 
specific aims of our study and to the databases that have been used (See Appendix).4 
We used this method to make the results comparable between studies.  
Studies that assess postoperative opioid use after any kind of standard operation were 
included. Further inclusion criteria were a minimum follow up of 3 months, a study 
population of adults (>18 years) and data specific to European hospitals/health settings. 
The broadest possible definition of “Europe” was used (the explicit countries can be 
found in the Search-String). No language restriction was applied.  Because we were 
interested in investigating standard prescribing behaviours, studies, where opioid use 
was directly influenced by the study design and cases that were not treated according to 
the standard of care, were excluded, for example intervention studies where the protocol 
was not followed. Reviews, Letters, Case Reports and qualitative studies were excluded. 
We considered only the studies published between January 2009 and 30th September 
2019, to reflect as much as possible current practices.  
The titles and abstracts of potentially eligible studies were screened by one author (TS). 
Screening the titles and abstracts was combined into one step. After the title and 
abstracts were screened, two authors (TS and PF) checked all the studies identified as 
potentially eligible regarding inclusion/exclusion criteria and discrepancies were resolved 
by consensus. The full text of the selected studies was read completely. 
A data collection form was designed and tested to determine those included and then 
used for the data extraction.  
The country of the study, the study design, the operation type, the study size, the follow-
up-time and the proportion of opioid users at 3, 6, 9 and 12 months was extracted. As 
some studies reported only post-discharge uses, this time was considered as 
postoperative and this information was recorded in the extraction form. Further details 
like age limitations, specific definitions of “opioid use” and information about preoperative 
users, were recorded too. 
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All included studies were appraised with the Grading of Recommendations Assessment, 
Development and Evaluation (GRADE) approach.8 The risk of bias in individual studies 
was assessed on a study and an outcome level.  The reasons for decreasing the level 
of evidence were discussed by TS and PF and can be found in the extraction form in the 
appendix. 
Outcomes 
The main outcome is the rate of persistent postoperative opioid users, which has been 
extracted for every type surgical procedure at 3 months after surgery. The percentages 
of persistent opioid use have been derived from the proportions of users. When possible, 
the risk of becoming a persistent opioid user has been estimated for opioid naïve users, 
preoperative opioid users and patients undergoing different surgeries. The 95% CIs were 
calculated with a simple asymptotic method without continuity correction (“Wald 
Method”).9 
A qualitative data synthesis was done. The rate of opioid users after 3 to 6 months is 
categorised into groups, depending on the type of surgery. These categories are 
described and compared in terms of quality and results. Regarding the data 
heterogeneity, a data aggregation was not possible. Additional analyses included the 
comparison of operation types and of opioid naïve and preoperative opioid users. 
Because the used data shows a big heterogeneity, a meta-analysis is not possible. 
The following potential bias has been considered: Limitations in the design (i.e. 
prospective vs. retrospective, a large loss to follow-up), eligibility criteria (less or more 
restrictive in terms of population or outcomes), unexplained heterogeneity or 
inconsistency of results, imprecision of results (few participants) and the risk of 
publication bias (included the selective outcome reporting bias). 
 
RESULTS  
Study selection  
A total of 1307 articles were found. After the removal of duplicates, the title and abstracts 
of 1018 articles were screened. 903 articles were excluded, and 115 articles underwent 
a full-text screen. In some cases, contact to the authors was necessary to have further 




A general overview of the size, the publication year, the country of investigation and the 
investigated surgery types of the studies can be found in table 1. Two studies each are 
from Denmark,10,19 the UK12,13 and France.20,21 The other studies are from Germany,17 
Belgium,18 Norway,16 Spain15 and the Netherlands,14 and the study of Dengler et al. 
reports of patients in Germany, Belgium, Sweden and Italy.11 
The opioid use was either reported by the patients or was extracted as prescription data 
from national or hospital databases. An overview of the assessment methods can be 
found in the Appendix. 
The Overall Quality of Evidence was assessed with GRADE and can be found in the 
Appendix. Three studies have an overall high quality of evidence,10,16,17 two studies are 
considered as having moderate quality14,19 and 7 studies were either rated as having a 
low18,20,21 or very low quality.11-13,15 According to the assessment of study limitations and 
risk of bias, 5 of 12 studies have no serious study limitations,10,16,17,19,21 4 studies have 
serious limitations11,14,18,20 and 3 studies12,13,15 have very serious limitations (Appendix). 
Results of individual studies (Table 1) 
Hip surgery 
Five of 12 studies involved either total hip arthroplasty (THA), hip fracture surgeries or 
sacroiliac joint arthrodesis. Hip surgeries are therefore the most investigated type of 
surgery in the included studies. Simoni et al (2019), the study with the biggest study size, 
analysed hip surgeries as well.10 They included 69,456 hip fracture surgery patients (≥ 
65 years) in Denmark. After 3 to 6 months 33.8% (CI 95%: 33.4 - 34.2) of these patients 
were using opioids. The second biggest study is from Blågestad et al. (2016), who 
followed 39,688 THA patients in Norway.16 Their results showed that 3 to 6 months after 
the surgery 14.7% (CI 95%: 14.5 – 15.0) “redeemed 1 or more prescriptions during the 
period studied”. Lindestrand et al. (2015) analysed in a retrospective cohort the opioid 
consumption of 413 hip fracture surgery patients in Denmark.19 Three months after 
hospital discharge 36 % (CI 95%: 31.4 - 40.6) were taking opioids. Vanaclocha et al. 
(2018) compared 423 adults undergoing different kind of sacroiliac joint pain surgery in 
Spain up to 6 years after their treatment.15 Twenty-seven patients had an invasive 
sacroiliac joint fusion (SIJF). Six months after the operation, 7.4% (CI 95%: -2.5 - 17.3) 
(2 patients) of the SIJF patients used opioids. A limitation of these results is the existence 
of an inclusion bias related to the access to surgery. Dengler et al (2019) assessed the 
long-term outcomes of sacroiliac joint arthrodesis or a conservative management for 
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chronic low back pain attributed to the sacroiliac joint in a randomised trial.11 This study 
was conducted in Germany, Belgium, Sweden and Italy and a total of 52 patients had a 
sacroiliac joint arthrodesis. After 3 months about 41% of these patients took opioids. 
Because no exact number was available for 3 months follow-up, this information was 
extracted from figure 4 in the paper.  
Knee surgery 
Two studies assessed the long-term opioid consumption after total knee arthroplasty 
(TKA). Grosu et al (2016) conducted a prospective cohort study in Belgium analysing 
TKA patient.18 Three months after surgery 21 of 76 patients (28 % (CI 95%: 17.9 - 38.1)) 
reported a regular intake of opioids. In 2018, Fenten et al. analysed TKA patients aged 
50 to 80 in the Netherlands.14 They randomised the patients to be either treated with a 
femoral nerve catheter (FNB) or with local infiltration (LIA). After 3 months 7.9 % (CI 
95%: 0 - 16.5) of 38 FNB patients and 13.2 % (CI 95%: 2.7 - 23.7) of 40 LIA patients 
were opioid users. 
Knee and hip surgery 
Curry et al. (2019) and Laufenberg-Feldmann et al. (2016) assessed the long-term 
outcome from THA and TKA simultaneously.13,17 In the retrospective cohort study of 
Curry et al. (2019) the data of 79 THA and TKA patients in the UK were analysed.13  
Three months after hospital discharge 26 patients (33% (CI 95%: 22.6 - 43.3)) received 
an opioid prescription. Laufenberg-Feldmann et al (2016) observed the prevalence of 
pain of patients undergoing joint-, back- or urological-surgery 6 months after the 
operation.17 The study was conducted in Germany and 156 THA/TKA patients were 
included. After 6 months 8.7% (CI 95%: 4.3 - 13.1) of these patients were using opioids.  
A total of 9 studies that were included for the analysis, deal with hip or/and knee 
surgeries. The included surgery types are THA, TKA, hip fracture surgery and sacroiliac 
joint arthrodesis. The results show a wide variety of incidence rates of persistent opioid 
consumption. 3 to 6 months after surgery between 7.4% and 41% of patients are opioid 
users. Just taking the studies into account, which are having a moderate or high quality, 
give results between 7.4 % and 36 %. 
Other operation types 
Two studies observed the long-term outcomes of patients undergoing a thoracotomy. 
Chumbley at al. (2019) analysed 70 thoracotomy patients in the UK, that were not using 
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strong opioids preoperatively.12 The patients were randomised to receive either 
intravenous ketamine or saline placebo for 96 hours, starting 10 minutes prior surgery. 
34 patients were randomised in the “saline placebo” group and were relevant for us. Four 
patients (11.76% (CI 95%: 0.9 - 22.6)) were opioid users 3 months after surgery. The 
second study analysing thoracotomy patients was just including opioid naïve patients in 
their randomised, double-blind, placebo-controlled clinical trial.20 Just the placebo group 
was considered here, because the intervention group was additionally treated with 
ketamine, not being part of the standard of care. After 4 months a follow-up of 35 placebo 
group patients was reported. At this time no participant (0%) reported opioid 
consumption.  
Beside joint-surgery patients, Laufenberg-Feldmann et al. (2016) analysed 184 back-
surgery patients (nucleotomy / spondylodesis) and 151 urological-surgery patients 
(cystectomy, prostatectomy, nephrectomy) as well.17 After 6 months 13.6% (CI 95%: 8.6 
- 18.6) of back patients and 2.0% (CI 95%: 0 - 4.2) of urological-surgery patients used 
opioids.  
In the 2015 published study of Fuzier et al. 1292 patients undergoing trauma or 
orthopaedic surgery were analysed.21 Assuming that patients did not combine different 
types of opioids, a total of 12.15% (CI 95%:10.7 - 14.3) of the observed patients were 
opioid users 3 months after surgery. 
Opioid naïve patients vs. pre-users 
The direct comparison of opioid use between preoperative opioid users and opioid naïve 
patients was just made by Simoni et al. (2019).10 In their analysis 3 to 6 months after hip 
fracture surgery 21.8 % (CI 95%: 21.4 - 22.2) of 50,839 opioid naïve patients used 
opioids. In the smaller sample of 18,617 preoperative opioid users, 68% (CI 95%: 67.2 - 
68.7) were using opioids 3 to 6 months after operation. Lindestrand et al. (2015) and 
Dualé et al. (2012) gave information about the postoperative opioid use of opioid naïve 
patients.19,20 In the sample of Lindestrand et al. 2.9 % (CI 95%: 1.04 - 4.8) of opioid naïve 
hip fracture surgery patients used opioids after 6 months.19 Dualé et al. (2012) just 
analysed opioid naïve patients after thoracotomy in general.20 Of the 35 investigated 
patients, no one used opioids after 4 months (0%). 
Evolution 3 to 12 months after surgery 
Comparing the reported user rates at 3 and 12 months after surgery, shows a decrease 
in every area. In 5 of 7 scenarios (6 studies), that give information about use during the 
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follow up year, the absolute reduction of opioid users was smaller than 10 percentage 
points (Simoni et al.10: -5.6%; Dengler et al. (8): -2 %; Blågestad et al.16: -0.6 %; Fenten 
et al.14: FNB -2.5%; Chumbley et al.12: -8.19 %). Just Grosu et al.18 and Fenten et al.14 
(LIA group) reported a higher reduction of user rated from the third to the twelfth month 
after surgery (Grosu et al.18: -20%; Fenten et al.14: LIA -10.6%).  
 
Synthesis of results (Table 2) 
GRADE was used to evaluate the overall Quality of Evidence of the included studies. 
Five of 12 studies have a moderate or high quality. Due to different surgery types, 
different countries and different study approaches, there were multiple possible sources 
of heterogeneity. Orthopaedic surgeries are the most investigated surgeries in terms of 
long-term opioid use in Europe.  Hip surgeries for example show user rates between 7.4 
% and 41 % at 3 to 6 months follow up. Excluding studies with a low or very low quality, 
we see user rate of 14.7% to 36%.  
TKA alone and in combination with THA show similar results with user rates between 7.9 
and 33%.13,14,17,18 Excluding low and very low quality studies however leaves us with 
rates between 7.9 and 13.2 %.  
Two studies each are from Denmark, the UK and France, one study each is from the 
Netherlands, Spain, Norway, Germany and Belgium and one study was conducted in 
Germany, Belgium, Sweden and Italy at once. It needs to be noticed that both Danish 
studies analyse hip fracture surgeries, and both have similar user rates after 3 to 6 
months (Simoni et al. 201910: 33.8% (CI 95%: 33.4 - 34.2); Lindestrand et al. 201519: 
36% (CI 95%: 31.4 - 40.6)).  
 
DISCUSSION  
Summary of evidence  
In summary the incidence of persistent postoperative opioid use ranges from 2.0% to 
44.0%. Compared with Kent et al. (2019) this results have a smaller range, but especially 
in terms of arthroplasties, they are very similar.4 Kent et al. reported 5.5% to 32% 
persistent postoperative opioid users in the overall sample of arthroplasty surgeries, 
while we found rates of 7.9% to 33%. But compared with North America, there are just a 
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small number of studies in Europe investigating persistent postoperative opioid use. Kent 
et al. were able to include 46 studies in their qualitative analysis. Based on one study, 
preoperative opioid use seems to be a risk factor for persistent opioid use.10 This 
corresponds with the identified risk factors of Kent et al.  
Other risk factors are less clear. In Canada, age has been associated with a decreased 
proportion of patients that filled a postoperative opioid prescription. However, the initial 
prescription did not typically differ in older adults.22 In our study, it is difficult to isolate the 
effect of the age. However, the Simoni’s study, being the largest (69,456 patients) and 
the with a high level of evidence, showed high rate of persistent use of opioids after hip 
fracture surgery (more than 15% in opioid-naïve patients, and more than 60% in 
preoperative opioid users).10 
The comparison of these studies in terms of their country of origin and in terms of the 
surgery type is however just possible under the consideration of the huge variety of 
factors. In some studies, the authors report opioid use as a secondary outcome or opioid 
use is assessed as a parameter for pain.11,12,14,15,18,20,21 Therefore, information like 
preoperative use or opioid type is mostly missing. The over-representation or 
orthopaedic surgery is not explained. However, all these questions are essential to 
understand better the pathophysiology of chronic pain and the patients’ risk profile and 
should be urgently investigated.   
Interpretation in the context of postoperative persistent pain 
Surgery is a model to study the transition from acute to chronic pain, as it combines a 
scheduled trauma (the surgical procedure), the opportunity to dissect mechanisms 
implicated in the resolution of acute pain and its clinical correlate, their dysfunction 
leading to the transition into chronic states. It permits to investigate the impact of 
vulnerability factors (patient-related, i.e. the medical history, co-morbidities, genetics; 
but, also, the iatrogenic factors. In this context, opioids may have a role, either by under-
prescription (leading potentially to poor pain management), or by the use of high doses, 
that may lead to acute or chronic opioid-induced hyperalgesia (playing a potential role in 
the sensitization to pain of the central nervous system), and to persistent postoperative 
opioid use.23-25  
Limitations  
The biggest imitation of this study is the lack of sufficient data. The best approach to 
capture current postoperative opioid prescriptions, observational studies, was not used 
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for the methodology in 4 of the 12 included studies. Additionally, 7 of 12 studies did not 
have the primary aim to investigate opioid prescriptions.11,12,14,15,18,20,21 The different 
definitions of opioid consumption might be a limitation as well, because we can not be 
sure, if prescribed drugs, were redeemed and completely used by the patients. This 
information does not cover the size of the prescribed opioid package as well.  Moreover, 
patients might be using opioids for no operation related indications. Finally, we did not 
capture data at a patient-level, not permitting to integrate the use of non-opioid 
analgesics that may have changed during the study period, as other unidentified sources 
of heterogeneity between the studies. 
Perspective 
To come to a full conclusion in this question, further research is needed. One the one 
hand, more good quality data about user rates is required, but on the other hand the 
consequences of long-term opioid use need to be described better as well. Especially 
for non-arthroplasty-surgeries research is missing.  
There are strategies to tackle the so called “opioid epidemic” in the USA that could be 
easily adapted in European countries as well, if a problem with opioid use manifests. 
Quinlan et al (2019) proposed interventions like the “identification of patients at risk of 
developing CPSP” and of “patients developing opioid substance use disorder”, the 
“administration of both paracetamol and NSAIDs where safe”, “Opioid ‘light’ anaesthesia 
and avoidance of remifentanil”, the “avoidance of more addictive opioids”, a “limit 
duration of opioid prescription”, to “promote opioid weaning” and the “use of non-
pharmacological analgesic strategies” to patients, to “set realistic expectations regarding 
analgesia” and to “avoid repeat opioid prescriptions”.26 These could be either used to 
solve or to prevent opioid dependence, misuse of opioids and opioid related death but 
should be supported by more evidence. Either way a monitoring of the opioid prescription 
pattern in Europe may be beneficial. Finally, where a problem is confirmed, the opioid 
overuse as the problem of transition from acute to chronic pain could be elegantly 
addressed by the development of postoperative transitional pain units, acting after the 
hospital discharge.27 
Conclusions  
This systematic review of studies about persistent postoperative opioid use in Europe 
found that there is a reported range of 2.0% to 41.0% of opioid users three months after 
surgery. To give statements about specific countries or surgery types is not possible. 
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Therefore, we can neither confirm nor rule out a possible public health problem linked to 
the persistent use of opioids in Europe. 
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Figure 1 : Study flow diagram 
 
TABLES LEGENDS 
Table 1: Results of individual studies 
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PubMed: n= 48 













12 articles included 
Exclusion Criteria: 
- Study type: Systematic 
Review, Letter, Case 
Reports, Qualitative 
Studies 
- opioid use is 
influenced by study 
protocol 
Inclusion Criteria: 
- Follow-up ≥ 3 months 
- European Data 
- Intervention: 
Operation/Surgery 




Table 3: Results of individual studies 
Study Country Surgery Study Size n opioid users (time since 
surgery: %) 
Simoni et al. 
201910 
Denmark Hip fracture surgery  All patients: 69,456    
 
 






3 - 6 months: 33.8 %                                  
6 - 9 months: 29.7%                                          
9 - 12 months: 28.2 % 
opioid-naive:                                         
3 - 6 months: 21.8 %                                              
6 - 9 months: 17.8%                                        
9 - 12 months: 16.8 % 
preoperative opioid users:                                               
3 - 6 months: 68.0%                                                     
6 - 9 months: 64.8 %                                               
9 - 12 months: 62.4 % 







52 3 months: 41%                                                               
6 months: 41%                                                             
12 months: 39 %  
Chumbley et al. 
201912 
UK Thoracotomy  3 months: 34                                 
6 months: 32                                                 
12 months: 28 
3 months: 11.76 %                                               
6 months: 3.13 %                                               
12 months: 3.57 % 
Curry et al. 
201913 
UK TKA / THA  94 3 months: 33 %  
Fenten et al. 
201814 
Netherlands TKA  3 months:       
   FNB: 38 
   LIA: 40                            
12 months:   
    FNB 37 
    LIA 36  
3 months:  
   FNB 7.9 % 
   LIA 13.2%                                            
12 months:   
   FNB 5.4%  
   LIA: 2.6% 
Vanaclocha et al. 
201815 
Spain Sacroiliac joint fusion 
or denervation  
27 6 months:   7.4 %                                                      
Blågestad et al. 
201616 
Norway THA  39,688 3 - 6 months: 14.7 %                                                        
6 - 9 months: 14.4 %                                                   
9 - 12 months: 14.1 % 
Laufenberg - 
Feldmann et al. 
201617 
Germany Joint (THA, TKA)                                
Back (nucleotomy, 




Joint: 156                           
Back: 184                                              
Uro: 151
6 months:                                                 
Joint 8.7 %                                 
  Back 13.6%                                                   
  Uro 2.0 %  
Grosu et al. 
201618 
Belgium TKA  3 months: 76                                     
6 months: 74                                   
12 months: 68 
3 months:  28 %                                                 
6 months: 14 %                                                   
12 months: 8 %  
Lindestrand et al. 
201519 
Denmark Hip fracture surgery 413 3 months: 36%                                          
6 months: 30% 
                                                            
Opioid Naïve:  
6 months: 2.9% 
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Dualé et al. 
201220 
France Thoracotomy  Opioid naïve: 35 Opioid naïve: 
4 months: 0 %  
Fuzier et al. 
201521 
France Orthopaedic surgery 1292 3 months: 12.15 % 






Table 4: Persistent postoperative opioid users per category 
Operation 
Category 
Author Operation Opioid users (time since surgery: 
%) 
Hip Simoni et al. 201910 Hip fracture surgery  3 - 6 months: 33.8 % (CI 95%: 33.4 - 
34.2)           
Lindestrand et al. 201519 Hip fracture surgery  3 months: 36% (CI 95%: 31.4 - 40.6)   
Blågestad et al. 201616 THA  3 – 6 months: 14.7 % (CI 95%:14.5 -
15.0)  
Dengler et al. 201911 SI joint arthrodesis  3 months: 41% (CI 95%: 27.6 - 54.4)    
Vanaclocha et al. 201815 SI joint fusion or denervation  6 months: 7.4 % (CI 95%: -2.5 - 17.3)                                                
Knee  Fenten et al. 2018
14 TKA 3 months: 
FNB 7.9 % (CI 95%: -0.7 - 16.5) 
LIA 13.2% (CI 95%: 2.7 - 23.7)   
Grosu et al. 201618 TKA 3 months:  28 % (CI 95%: 17.9 - 38.1) 
Hip and Knee  Curry et al. 2019
13 TKA; THA   3 months: 33 % (CI 95%: 22.6 - 43.3) 
Laufenberg - Feldmann et 
al. 201617 
THA; TKA 6 months: 8.7 % (CI 95%: 4.3 - 13.1) 
Other  Laufenberg - Feldmann et 
al. 201617 
Nucleotomy; spondylodesis 6 months: 13.6% (CI 95%: 8.6 - 18.6)  
Fuzier et al. 201521  Trauma or orthopaedic surgery 3 months: 12.2 % (CI 95%:10.7 - 
14.3) 
Chumbley et al. 201912 Thoracotomy 3 months: 11.8 % (CI 95%: 0.9 - 22.6)    
Dualé et al. 201220 Thoracotomy (opioid naïve 
patients) 
4 months: 0 % (CI 95%: 0 - 0) 




6 months:  2.0 % (CI 95%: -0.2 - 4.2)  
TKA: Total Knee Arthroplasty; THA: Total Hip Arthroplasty; FNB: femoral nerve catheter; LIA: local infiltration 
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